Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of MET fusions as novel therapeutic targets sensitive to MET inhibitors in lung cancer.

Journal of translational medicine - 25 Feb 2023

Sun Dantong, Wu Weizheng, Wang Li, Qu Jialin, Han Qiman, Wang Huiyun, Song Shanai, Liu Ning, Wang Yongjie, Hou Helei

Abstract excerpt

INTRODUCTION: Alterations in the MET gene, including amplifications and exon 14 skipping mutations, have been identified as actionable oncogenic alterations. However, MET fusions are rarely detected in lung cancer, and their sensitivity to therapeutics has not been systematically analyzed. METHODS: The data from 30876 lung cancer patients from the LAVA database and 7966 patients from cBioPortal database were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Carcinoma, Squamous Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Crizotinib

Share to Lung Neoplasms

Share to Mutation

Share to Oncogene Proteins, Fusion

Share to Oncogenes

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 36829199
DOI: 10.1186/s12967-023-03999-7
PMCID: PMC9960416

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of MET fusions as novel therapeutic targets sensitive to MET inhibitors in lung cancer.PMID 36829199Read ↗

MET fusions are targetable genomic variants in the treatment of advanced malignancies.Semantic proximity Read ↗

MET Fusions in NSCLC: Clinicopathologic Features and Response to MET Inhibition.Semantic proximity Read ↗

Unveiling the Uncommon: Targeting Rare MET Fusions in NSCLC: A Comprehensive ReviewSemantic proximity Read ↗

The METeoric rise of MET in lung cancerSemantic proximity Read ↗

Analysis of MET kinase domain rearrangement in NSCLC.Semantic proximity Read ↗

Response and acquired resistance to MET inhibitors in de novo MET fusion-positive advanced non-small cell lung cancer.Semantic proximity Read ↗

MET alterations and their impact on the future of non-small cell lung cancer (NSCLC) targeted therapies.Semantic proximity Read ↗

Improved Survival Outcomes in Patients With MET-Dysregulated Advanced NSCLC Treated With MET Inhibitors: Results of a Multinational Retrospective Chart Review.Semantic proximity Read ↗

Molecular characterization of MET fusions from a large real-world Chinese population: A multicenter study.Semantic proximity Read ↗

MET alterations in advanced non-small cell lung cancer.Semantic proximity Read ↗

MET alterations in advanced non-small cell lung cancer.Semantic proximity Read ↗

MET alterations in NSCLC-Current Perspectives and Future Challenges.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.